Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B

Exclusion Criteria

• •Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before the dose of study vaccine, or planned use during the study period.
• •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose. For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
• •Administration of long-acting immune-modifying drugs at any time during the study period.
• •Previous hepatitis B booster vaccination since completion of the primary vaccination series with three or four doses of Engerix-B.
• •Planned administration of a vaccine not foreseen by the study protocol within 30 days preceding the dose of study vaccine, or planned administration during the study period, with the exception of seasonal influenza vaccine.
• •Any medical condition that in the judgment of the investigator places the subject at undue risk by participating in the study.
• •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
• •History of hepatitis B disease or episode of jaundice with unknown etiology.
• •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• •Major congenital defects or serious chronic illness (including insulin-dependent diabetes).
• •Acute disease and/or fever at the time of enrolment.
• •* Fever is defined as temperature ≥37.5°C for oral, axillary or tympanic route, or 38.0°C on rectal route.
• •* Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
• •Administration of immunoglobulins and/or any blood products during the period starting 3 months before the dose of study vaccine, or planned administration during the study period.
• •Drug and/ or alcohol abuse within the last 5 years.